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OBJECTIVE: It is important to analyze and track Epidermal Growth Factor Receptor (EGFR) mutation status for
predicting efficacy and monitoring resistance throughout EGFR-tyrosine kinase inhibitors (TKIs) treatment in non-
small cell lung cancer (NSCLC) patients. The objective of this study was to determine the feasibility and predictive
utility of EGFR mutation detection in peripheral blood. METHODS: Plasma, serum and tumor tissue samples from
164 NSCLC patients were assessed for EGFR mutations using Amplification Refractory Mutation System (ARMS).
RESULTS: Compared with matched tumor tissue, the concordance rate of EGFR mutation status in plasma and
serum was 73.6% and 66.3%, respectively. ARMS for EGFR mutation detection in blood showed low sensitivity
(plasma, 48.2%; serum, 39.6%) but high specificity (plasma, 95.4%; serum, 95.5%). Treated with EGFR-TKIs,
patients with EGFR mutations in blood had significantly higher objective response rate (ORR) and insignificantly
longer progression-free survival (PFS) than those without mutations (ORR: plasma, 68.4% versus 38.9%, P =
0.037; serum, 75.0% versus 39.5%, P = 0.017; PFS: plasma, 7.9 months versus 6.1 months, P = 0.953; serum,
7.9 months versus 5.7 months, P = 0.889). In patients with mutant tumors, those without EGFRmutations in blood
tended to have prolonged PFS than patients with mutations (19.7 months versus 11.0 months, P = 0.102).
CONCLUSIONS: EGFR mutations detected in blood may be highly predictive of identical mutations in
corresponding tumor, as well as showing correlations with tumor response and survival benefit from EGFR-TKIs.
Therefore, blood for EGFR mutation detection may allow NSCLC patients with unavailable or insufficient tumor
tissue the opportunity to benefit from personalized treatment. However, due to the high false negative rate in blood
samples, analysis for EGFR mutations in tumor tissue remains the gold standard.
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Lung cancer is the leading cause of cancer-related death worldwide
[1]. Non-small cell lung cancer (NSCLC) comprises approximately
85% of all lung cancer cases, of which more than 70% are initially
diagnosed with unresectable advanced disease [2,3]. Systemic
treatment, including molecular-targeted therapy, plays a central role
in the clinical management of NSCLC.
Small-molecule tyrosine kinase inhibitors (TKIs), such as gefitinib
and erlotinib, specifically target epidermal growth factor receptor
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EGFR mutations have been demonstrated to be the strongest
predictive biomarkers for the efficacy of EGFR-TKIs [4–8]. Patients
with EGFR activating mutations, mainly in-frame deletions in exon
19 (19Del) and L858R substitutions in exon 21, have dramatic tumor
responses and favorable survival benefit from EGFR-TKIs [9,10].
However, most responsive patients would eventually experience
progressive disease (PD). The secondary T790M mutation in exon
20 accounts for approximately 50% of the mechanism of acquired
resistance [11]. Hence, it is of great clinical importance to analyze
and track EGFR mutation status for predicting efficacy and
monitoring resistance throughout EGFR-TKIs treatment in NSCLC
patients.
EGFR mutation analysis is recommended in National Comprehen-
sive Cancer Network clinical guidelines for NSCLC. Nevertheless,
a national survey shows that only 9.6% of NSCLC patients with
stage IIIb or IV disease had EGFR-related testing performed in
China [12]. Partially because tumor tissue, the optimal DNA
source for EGFR mutation analysis, is always difficult to obtain.
Most NSCLC patients presenting inoperable advanced disease
cannot provide surgical samples, whereas biopsy samples may not
be sufficient for both pathologic examination and mutation
analysis. Besides, many patients refuse repeated biopsy at the
time of disease progression. However, peripheral blood of cancer
patients frequently contains circulating free DNA (cfDNA) derived
from tumor cells, which has been used to detect tumor-specific
alterations [13]. Moreover, blood sampling is minimally invasive,
readily accessible, relatively repeatable. Thus, using blood for
EGFR mutation identification and follow-up shows promise.
Amplification Refractory Mutation System (ARMS) has been
extensively used in large clinical trials, and has been proved to be
a stable, highly sensitive and specific method for EGFR mutation
detection in tumor tissue. This method was shown to be able to
detect mutations in samples containing as little as 1%mutated DNA
[4,14–16]. In this study ARMS was used to detect EGFRmutations
in plasma, serum and tumor tissue samples of NSCLC patients. The
objective of this study was to determine the feasibility and predictive
utility of EGFR mutation detection in blood.Patients and Methods
Patients
To be eligible for this study, patients were required to have
pathologically confirmed NSCLC and available plasma, serum or
tumor tissue for EGFR mutation analysis. 164 patients were enrolled
in this study from October 2011 to October 2012 at Shanghai
Pulmonary Hospital. Patients’ clinicopathologic characteristics,
treatment regimens, tumor responses and survival outcomes were
recorded. Smoking history was based on records at patients’ first clinic
visit and having smoked more than 100 cigarettes in a lifetime was
used to define smokers. Performance status was evaluated using the
Eastern Cooperative Oncology Group criteria. Tumor response
was assessed according to the Response Evaluation Criteria in
Solid Tumours guidelines. Written informed consent was obtained
from all participants, and provision of plasma, serum and tumor tissue
for EGFR mutation analysis was optional. This study was approved
by the Institutional Ethics Committee of Shanghai Pulmonary
Hospital.Sample Collection
Plasma was collected from 141 patients and serum from 108
patients. Plasma/serum was separated from 4 mL peripheral blood by
centrifugation at 1,000 rpm for 10 min at 4°C within 4 hours after
collection and stored at -80°C until DNA extraction. Tumor tissue
obtained from 142 patients via biopsy was put into RNAlater solution
(Ambion, Austin, Texas, USA) and stored at -80°C until DNA
extraction. All tumor tissue samples went through pathologic
evaluation to confirm the diagnosis of NSCLC.
DNA Extraction
DNA was extracted from 1 ml plasma/serum or 2-20 mg tumor
tissue. The DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany)
was used to extract DNA according to the manufacturer’s
instructions. The concentration and purity of DNA were determined
by NanoDrop 2000 Spectrophotometer (Thermo Scientific, Wal-
tham, USA). DNA extracted from tumor tissue was standardized to 1
ng/μL, whereas cfDNA extracted from plasma/serum was used for
EGFR mutation analysis immediately without standardization.
EGFR Mutation Analysis
The Human EGFR Gene Mutations Fluorescence Polymerase
Chain Reaction Diagnostic Kit (Amoy Diagnostics, Xiamen, China),
which is based on ARMS technology, was used to detect the 19Del,
L858R and T790M mutation according to the manufacturer’s
instructions. Briefly, all reactions were performed in 25 μL volumes
including 4.7 μL of template DNA, 0.3 μL of Taq polymerase and 20
μL of reaction buffer mix. Real-time PCR was carried out using
MX3000P real-time PCR machine (Stratagene, La Jolla, CA, USA)
under following conditions: (1) initial denaturation at 95°C for 5
min, (2) 15 cycles of 95°C 25 s, 64°C 20 s and 72°C 20 s, (3) 31
cycles of 93°C 25 s, 60°C 35 s and 72°C 20 s with fluorescence FAM
and HEX reading at 60°C of each cycle in phase 3. Data analysis was
performed with MxPro v4.10 (Stratagene, La Jolla, CA, USA). Cycle
threshold (Ct) represents the threshold at which the signal was
detected above background fluorescence. ΔCt values were calculated
as the difference between the mutation Ct and control Ct. Positive
results were defined as follows: (1) Ct is lower than 26, (2) Ct is
higher than 26 and ΔCt is lower than the cut-off ΔCt value (11 for
19Del and L858R, 7 for T790M).
Statistical Analysis
SPSS statistical software, version 17.0 (SPSS, Inc., Chicago, IL, USA)
was used to analyze the data. The comparison of EGFR mutation rate
among different sample types and the correlation between EGFR
mutation status and clinicopathologic characteristics as well as response
to EGFR-TKIs were evaluated using Chi-square test or Fisher’s exact
test. Cohen’s kappa statistic and McNemar’s test were used to analyze
the concordance of EGFR mutation status between matched samples.
Progression-free survival (PFS) with EGFR-TKIs treatment according
to EGFR mutation status was estimated by Kaplan-Meier method and
compared using log-rank test. A two-sided P value less than 0.05
indicated statistical significance.Results
Patient Characteristics
In total, 164 Chinese patients with NSCLC were enrolled in this
study from October 2011 to October 2012 at Shanghai Pulmonary
Table 1. Patient Characteristics.
Characteristics No. of patients (n = 164) Percentage (%)
Age (years)
Median 58
Range 32-81
Gender
Female 68 41.5
Male 96 58.5
Smoking history
Never smoker 84 51.2
Smoker 80 48.8
Histology
Adenocarcinoma 128 78
Squamous cell carcinoma 18 11
Adenosquamous carcinoma 5 3
NSCLC NOS 13 8
Stage
IIIb 14 8.5
IV 131 79.9
Postoperative relapse 19 11.6
Performance Status
0-1 151 92.1
2 9 5.5
3-4 4 2.4
NSCLC, non-small cell lung cancer; NOS, not otherwise specified.
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Table 1. During this study, 96 patients didn’t receive EGFR-TKIs,
19 received EGFR-TKIs as first-line therapy, 32 as second-line
therapy and 17 as third-line or subsequent therapy. Of 68 patients
who received EGFR-TKIs, 51 had their samples collected before
EGFR-TKIs treatment and 17 after PD to EGFR-TKIs.
EGFR Mutation Status
A total of 141 plasma samples, 108 serum samples and 142 tumor
tissue samples were available for EGFR mutation analysis (Table 2).
EGFRmutations were detected in 66 (46.5%) tumor tissue samples, of
which 38 samples harbored a 19Del, 27 a L858R and 8 a T790M
(concurrent with 19Del in 6 and L858R in one). 36 (25.5%) plasma
samples exhibited EGFRmutations, including 22 with 19Del, 14 with
L858R and 6 with T790M (concurrent with 19Del in 4 and L858R in
one). One plasma sample exhibited both 19Del and L858R. In serumTable 2. EGFR Mutation Status.
cfDNA EGFR mutation status Tumor EGFR mutation status
19Del only L858R only T790M only
Plasma
19Del only 13 0 0
L858R only 0 9 0
T790M only 0 1 0
19Del and L858R 0 0 0
19Del and T790M 1 0 0
L858R and T790M 0 1 0
Wild type 14 12 1
Unknown 4 4 0
Total 32 26 1
Serum
19Del only 7 0 0
L858R only 0 6 0
T790M only 0 0 0
19Del and T790M 1 0 0
Wild type 13 14 0
Unknown 11 6 1
Total 32 26 1
EGFR, epidermal growth factor receptor; cfDNA, circulating free DNA; Unknown, no sample availasamples, EGFRmutation rate was 22.2%. 24mutation-positive serum
samples included 14 with 19Del, 9 with L858R and 3 with T790M
(concurrent with 19Del in 2). EGFR mutation rate was significantly
higher in tumor tissue than in plasma (46.5% versus 25.5%, P b
0.001) and serum (46.5% versus 22.2%, P b 0.001).
Correlation between EGFR Mutation Status and Clinico-
pathologic Characteristics
The correlation between EGFR mutation status and patients’
clinicopathologic characteristics was summarized in Table 3. In
tumor tissue, EGFR mutation status was correlated with patients’
gender, smoking history and histology. EGFR mutation rate was
significantly higher in females than in males (60.0% versus 36.6%,
P = 0.006), in never smokers than in smokers (55.4% versus 36.8%,
P = 0.026) and in patients with adenocarcinoma than in those with
other histology (53.7% versus 23.5%, P = 0.002). In blood samples,
EGFR mutation status was only associated with histology. Patients
with adenocarcinoma had significantly higher mutation rate than
those with other histology in both plasma (30.0% versus 9.7%, P =
0.022) and serum (26.7% versus 4.5%, P = 0.024).
Comparison of EGFR Activating Mutation Status in Different
Sample Types
→ Plasma versus Tumor Tissue
EGFR mutation status was analyzed in 121 patients who
provided plasma andmatched tumor tissue samples (Table 4). 89
patients had identical EGFRmutation status in both plasma and
tumor tissue, including 27 with activatingmutations and 62with
wild type. Discrepantmutation results were observed: 29 patients
with mutant tumors had no mutation in matched plasma,
whereas 3 patients with mutant cfDNA had no mutation in
corresponding tumor tissue. The concordance rate of EGFR
mutation status between plasma and tumor tissue was 73.6%
(89/121). Compared with tumor tissue, the sensitivity and
specificity for EGFRmutation detection in plasma by ARMSwas
48.2% (27/56) and 95.4% (62/65), respectively. The false
negative rate was high: 51.8% (29/56) of patients with EGFR
mutant tumor were identified as wild type in plasma.19Del and T790M L858R and T790M Wild type Unknown Total
2 0 1 1 17
0 1 1 1 12
0 0 0 0 1
0 0 1 0 1
1 0 0 2 4
0 0 0 0 1
2 0 61 15 105
1 0 12 2 23
6 1 76 22 164
3 0 1 1 12
0 1 1 1 9
0 0 0 1 1
1 0 0 0 2
2 0 41 14 84
0 0 32 6 56
6 1 76 22 164
ble.
Table 3. Correlation between Clinical Characteristics and EGFR Mutation Status.
Characteristic Tumor tissue (n = 142) Plasma (n = 141) Serum (n = 108)
Mutation Wild type P values Mutation Wild type P values Mutation Wild type P values
Age 0.352 0.269 0.133
≥65 years 13 20 6 27 3 23
b65 years 53 56 30 78 21 61
Gender 0.006 0.790 0.877
Female 36 24 16 44 11 37
Male 30 52 20 61 13 47
Smoking history 0.026 0.136 0.108
Never 41 33 23 52 17 44
Current/former 25 43 13 53 7 40
Histology 0.002 0.022 0.024
Adenocarcinoma 58 50 33 77 23 63
Non-adenocarcinoma 8 26 3 28 1 21
Stage 0.445 0.831 0.061
IIIb-IV 60 66 33 95 24 73
Postoperative replase 6 10 3 10 0 11
Performance Status 0.724 0.729 1.000
0-1 63 71 34 96 22 76
≥2 3 5 2 9 2 8
EGFR, epidermal growth factor receptor.
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For EGFR mutation analysis 92 patients provided serum and
matched tumor tissue samples (Table 4). 61 patients exhibited
identical EGFRmutation status in both serum and tumor tissue,
including 19 with activating mutations and 42 with wild type.
Discrepant results were observed: 29 patients with mutant
tumors had no mutation in corresponding serum, whereas 2
patients withmutant cfDNAhad nomutation inmatched tumor
tissue. The concordance rate of EGFR mutation status between
serum and tumor tissue was 66.3% (61/92). Compared with
tumor tissue, the sensitivity and specificity of EGFR mutation
detection in serum by ARMS was 39.6% (19/48) and 95.5%
(42/44), respectively. The false negative rate was high: 60.4%
(29/48) of patients with EGFRmutant tumor were identified as
wild type in serum.
→ Plasma versus Serum
94 patients provided plasma and paired serum samples. 82
patients exhibited identical EGFR mutation status in both
plasma and serum, including 17 with activating mutations and
65 with wild type. Discordant results were observed: 9 patients
had mutant cfDNA in plasma but not in serum, whereas 3
patients had mutant cfDNA in serum but not in plasma. The
concordance rate of EGFR mutation status between plasma
and serum was 87.2% (82/94). The kappa coefficient of 0.657
was statistically significant (P b 0.001), whereas the McNe-
mar’s test showed no significant difference (P = 0.146).Table 4. Comparison of EGFR Activating Mutation Status in Different Sample Types.
Sample Tumor tissue Total Concordance
rate
Kappa coefficient
Mutation Wild type
Plasma 73.6% 0.450(P b 0.001)
Mutation 27 3 30
Wild type 29 62 91
Total 56 65 121
Serum 66.3% 0.342(P b 0.001)
Mutation 19 2 21
Wild type 29 42 71
Total 48 44 92
EGFR, epidermal growth factor receptor; PPV, positive predictive value; NPV, negative predictive vaComparison of EGFR T790M Mutation Status in Different
Sample Types
T790M was detected in 14 (8.5%) patients. Among them, one
patient exhibited T790M concurrent with 19Del in matched plasma,
serum and tumor tissue, whereas 10 patients had discrepant results
between blood and tumor tissue.
Correlation between EGFR Mutation Status and Response to
EGFR-TKIs
In 68 patients who received EGFR-TKIs, the correlation between
EGFR mutation status and response to EGFR-TKIs was analyzed
(Table 5). For tumor tissue, objective response rate (ORR) of patients
with or without EGFR activating mutations was 68.4% (26/38) and
10.5% (2/19), respectively (P b 0.001). For plasma samples, ORR of
patients with or without EGFR activating mutations was 68.4%
(13/19) and 38.9% (14/36), respectively (P = 0.037). For serum
samples, ORR of EGFR activating mutation positive and negative
patients was 75.0% (12/16) and 39.5% (15/38), respectively (P =
0.017). ORR of patients with EGFR mutant tumor was consistent to
that of patients with EGFRmutant cfDNA in plasma (P = 1.000) and
serum (P = 0.751), whereas ORR of patients with wild-type tumor
was significantly lower than that of patients with wild-type cfDNA in
plasma (P = 0.028) and serum (P = 0.024).
Of 17 patients who provided samples after PD to EGFR-TKIs,
9 (52.9%) exhibited T790M concurrent with an EGFR activating
mutation. In addition, one patient with L858R in tumor tissue butMcNemar's
test
Sensitivity Specificity False
positive
rate
False
negative
rate
PPV NPV
P b 0.001 48.2% 95.4% 4.6% 51.8% 90.0% 68.1%
P b 0.001 39.6% 95.5% 4.5% 60.4% 90.5% 59.2%
lue.
Table 5. Correlation between EGFR Activating Mutation Status and Response To EGFR-TKIs.
Sample EGFR activating mutation status CR + PR SD + PD Total
Tumor Tissue Mutation 26 12 38
Wild type 2 17 19
Total 28 29 57
Plasma Mutation 13 6 19
Wild type 14 22 36
Total 27 28 55
Serum Mutation 12 4 16
Wild type 15 23 38
Total 27 27 54
EGFR, epidermal growth factor receptor; CR, Complete Response; PR, Partial Response; SD,
Stable Disease; PD, Progressive Disease.
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PD after 1.4 months.
Correlation between EGFR Mutation Status and Survival
The correlation between EGFR mutation status and median PFS
time in patients treated with EGFR-TKIs was assessed. For tumor
tissue, PFS for patients with or without EGFR activating mutations
was 13.6 months (95% confidence interval [CI], 9.9 to 17.3) and
2.1 months (95% CI, 0.8 to 3.4), respectively. The difference was
statistically significant (P b 0.001, Figure 1A). For plasma samples,
patients with EGFR activating mutations had a PFS of 7.9 months
(95% CI, 1.6 to 14.1) compared with 6.1 months (95% CI, 2.7 to
9.6) for patients with wild-type EGFR (P = 0.953, Figure 1B). For
serum samples, patients harboring EGFR activating mutations had a
longer PFS of 7.9 months (95% CI, 6.5 to 9.2) than 5.7 monthsFigure 1. Progression-free survival (PFS) curves for 68 patients trea
inhibitors. A, PFS by EGFR activating mutation status in tumor tissue
EGFR activating mutation status in serum. D, PFS by EGFR activatin
positive for EGFR activating mutations; M-, negative for EGFR activa(95% CI, 2.1 to 9.2) for patients without mutations (P = 0.889,
Figure 1C). Moreover, PFS of patients with EGFR mutant tumors
was consistent to that of patients with EGFR mutant cfDNA in
plasma (P = 0.094) and serum (P = 0.176), whereas PFS of patients
with wild-type tumor was significantly shorter than that of patients
with wild-type cfDNA in plasma (P = 0.023) and serum (P = 0.023).
Further, all 68 patients received EGFR-TKIs were stratified into 4
subgroups based on their mutational genotypes: (1) positive for
EGFR activating mutations in both tumor tissue and blood (n = 20),
(2) positive for EGFR activating mutations in tumor tissue but
negative in blood (n = 18), (3) positive for EGFR activating mutations
in blood but negative in tumor tissue (n = 4), and (4) negative for
EGFR activating mutations in both tumor tissue and blood (n =
26). PFS for each group was graphed in Figure 1D. Patients in
subgroup two had a favorable PFS of 19.7 months (95% CI, 11.5 to
28.0), compared with 11.0 months (95% CI, 3.1 to 19.0) of those in
subgroup one (P = 0.102) and 1.7 (95% CI, 0.9 to 2.5) months of
those in subgroup three (P b 0.001). Patients in subgroup four had a
comparable PFS of 2.3 months (95% CI, 0.3 to 4.3) with those in
subgroup three (P = 0.508).Discussion
EGFR mutation analysis is recommended in clinical practice to direct
personalized management for NSCLC patients. This study demon-
strates the possibility of using blood to detect EGFR mutations,
though tumor tissue remains the best sample.ted with epidermal growth factor receptor (EGFR)-tyrosine kinase
. B, PFS by EGFR activating mutation status in plasma. C, PFS by
g mutation status in both tumor tissue and blood samples. M+,
ting mutations.
346 Blood for EGFR Mutation Detection in NSCLC Li et al. Translational Oncology Vol. 7, No. 3, 2014The concordance of EGFR mutation status between blood and
tumor tissue has been reported to be varying from 58.3% to 93.1%,
with minimal false positive rate and variable false negative rate [17–21].
This study showed that compared with matched tumor tissue the
concordance rate in plasma and serum was 73.6% and 66.3%,
respectively. ARMS for EGFR mutation detection in cfDNA showed
low sensitivity but high specificity. High specificity led to low false
positive rate, suggesting that EGFR mutations identified in blood may
be highly predictive of identical mutations in corresponding tumor.
Low sensitivity caused high false negative rate, which was responsible for
the significantly lower EGFR mutation rate in blood compared with
tumor tissue. Thus, EGFRmutation-negative results in blood should be
interpreted with caution as more than half of patients with EGFR
mutant tumors were not detected in cfDNA by ARMS.
It is notable that 41 patients with mutant tumors had no detectable
EGFR mutations in matched blood samples. This phenomenon has
been observed in previous studies [18,22,23]. The trace amount and
low percentage of mutant cfDNA could be below the detection limit
of ARMS, giving rise to false negative results in blood. Another
possible explanation is that prolonged storage of blood samples
resulted in a decrease in the quantity of DNA extracted, thus affecting
EGFR mutation detection [24]. In contrast, 5 patients with mutant
cfDNA had no corresponding mutations in matched tumor tissue.
This phenomenon has also been reported and could be explained by
tumor heterogeneity: these biopsied tumor tissue samples may not
carry the EGFRmutations detected in blood, because these mutations
come from different parts of the tumor [25–27]. However, 4 of these
5 patients received EGFR-TKIs and had a comparable PFS with those
who exhibited wild type in both blood and tumor tissue, suggesting
that these mutations detected in blood could be false positive results.
There have been a limited number of studies on the correlation
between EGFR mutation status in cfDNA and efficacy of EGFR-
TKIs [28–32]. Though the researchers tend to agree that EGFR
activating mutations in cfDNA may be predictive of better response
to EGFR-TKIs, they are still uncertain whether EGFR mutation
status in cfDNA can predict survival benefit from EGFR-TKIs. In a
subgroup analysis of IPASS, ORR was 75.0% (18/24) and 27.1%
(19/70) with gefitinib in patients with or without EGFR mutant
cfDNA, respectively. PFS was significantly longer with gefitinib than
carboplatin/paclitaxel in the cfDNA mutant subgroup (hazard ratio
[HR], 0.29; 95% CI, 0.14-0.60; P b 0.001) but not in the cfDNA
wild-type subgroup (HR, 0.88; 95% CI, 0.61-1.28; P = 0.50) [22].
Xu et al. reported that an significant correlation between EGFR
mutations status in plasma and tumor response to gefitinib was
observed using ARMS but not denaturing high-performance liquid
chromatography (DHPLC), whereas no association between EGFR
mutation status in plasma and PFS or overall survival (OS) was
observed no matter using ARMS or DHPLC [33]. Bai et al. detected
EGFR mutations in plasma using DHPLC and found that about
62.2% of patients with EGFR mutations responded to gefitinib,
whereas 37.8% of patients with wild-type EGFR also responded.
They noted that patients with EGFR mutant cfDNA had a
significantly longer PFS than those with wild-type cfDNA
(11.1 months versus 5.9 months, P = 0.044), though no difference
in OS was seen [25].
In the current study, patients with EGFR activating mutations in
tumor tissue had significantly greater ORR and longer PFS with
EGFR-TKIs, which accords with the finding of previous clinical trials
[4–8]. Patients harboring EGFR activating mutations in cfDNA alsohad significantly higher ORR, which was consistent to that of patients
withmutant tumors. In addition, patients withmutant cfDNA tended to
have longer PFS than those with wild-type cfDNA, though the difference
was not significant. These data suggest that EGFR activating mutations
detected in blood may be predictive of improved tumor response and
survival benefit from EGFR-TKIs. But patients with wild-type cfDNA
had significantly higher ORR and longer PFS than those with wild-type
tumors due to the presence of false negative results, suggesting thatEGFR
mutation-negative results detected in blood by ARMS is inferior to that in
tumor tissue with respect to predicting clinical outcomes.
This study showed that in patients with EGFR mutant tumors
those with wild-type cfDNA tended to have prolonged PFS compared
with patients harboring corresponding mutant cfDNA. Similarly, a
subgroup analysis of EURTAC indicated that in European patients with
advanced EGFR mutation-positive NSCLC who received erlotinib as
first-line therapy, the presence of mutant cfDNA in serum was associated
with reduced PFS (HR, 0.48; 95% CI, 0.22-0.97; P = 0.04) and OS
(HR, 0.46; 95% CI, 0.25-0.84; P = 0.02) [34]. For patients who
provided pretreatment samples, the presence ofEGFRmutations in blood
may correlate with severe tumor burden, which contributes to higher
proportion of tumor-derived cfDNA. Zhao et al. and Zhang et al. found
that there were more detectableEGFRmutations in plasma from patients
with advanced disease or patients with poorly differentiated tumors
[21,35]. Park et al. reported that tumor burden was predictive of inferior
survival in NSCLC patients with EGFR mutant tumor who received
gefitinib [36]. For patients who provided posttreatment samples, therapy-
related EGFR mutation status shift from mutation to wild type may
correlate with better response, thus affecting survival benefit. Yung et al.
found that plasma concentrations of EGFR mutations could decline to
undetectable level after EGFR-TKIs treatment in responsive patients
[23]. Besides, Bai et al. reported that patients whose EGFR mutation
status in cfDNA changed from mutant state to wild type after
chemotherapy had significantly better clinical response [37]. Dowson
et al. demonstrated that cfDNA could provide the earliest measure of
treatment response [38]. Hence, serial changes of EGFRmutation status
in cfDNA during follow-up period could be informative in monitoring
treatment response and predicting survival benefit. However, novel
ultrasensitive methods would be preferable, so that smaller changes in
cfDNA mutation status can be monitored in a better way.
The secondary T790M mutation has been reported to be present
in about half of NSCLC patients with acquired resistance to EGFR-
TKIs and is usually concurrent with activating mutations, which is
consistent with this study [39]. Rosell et al. and Su et al. reported that
patients with T790M-positive tumors before EGFR-TKIs treatment
had a shorter PFS than those having T790M-negative tumors
[40,41]. In this study one patient, with L858R in tumor tissue but
T790M in plasma before EGFR-TKIs treatment, directly experienced
PD after 1.4 months. Sakai et al. reported that when patients under
65 years who had partial response to EGFR-TKIs were grouped
according to their T790M mutation status in plasma, patients with
T790M had a significantly shorter PFS than patients without T790M
[42]. These data suggest that T790Mmutations in cfDNAmay aid in
monitoring resistance and predicting efficacy of EGFR-TKIs.
There were several limitations of this study. The sample size was
relatively small and samples were not well matched. Besides, this
study was not specifically designed to evaluate EGFR-TKIs
treatment. Notwithstanding its limitations, this study demonstrates
that EGFR mutations detected in blood of NSCLC patients by
ARMS may be highly predictive of identical mutations in
Translational Oncology Vol. 7, No. 3, 2014 Blood for EGFR Mutation Detection in NSCLC Li et al. 347corresponding tumor, as well as showing correlations with tumor
response and survival benefit from EGFR-TKIs. However, due to the
method’s low sensitivity in blood samples, tumor tissue remains the
best sample for EGFR mutation analysis. Further investigations
involving appropriate methodologies to decrease false negatives in
cfDNA-based EGFR mutation analysis are warranted.
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